These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35963337)

  • 1. Practical Guide to New Treatments for SARS-CoV-2 Infection in Dermatology Patients Being Treated With Common Immunomodulators.
    Viedma-Martínez M; Gallo-Pineda G; Jiménez-Gallo D
    Actas Dermosifiliogr; 2023 Jan; 114(1):49-53. PubMed ID: 35963337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.
    Karadag AS; Aslan Kayıran M; Lotti T; Wollina U
    Dermatol Ther; 2020 Sep; 33(5):e13686. PubMed ID: 32458530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm.
    Valero-López G; Carreón-Guarnizo E; Hernández-Clares R; Iniesta-Martínez F; Jiménez-Veiga J; Moreno-Docon A; Iborra-Bendicho MA; Aznar-Robles E; Hellín-Gil MF; Morales-Ortiz A; Meca-Lallana JE
    Neurologia (Engl Ed); 2020; 35(6):357-362. PubMed ID: 32591152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
    Elens L; Langman LJ; Hesselink DA; Bergan S; Moes DJAR; Molinaro M; Venkataramanan R; Lemaitre F
    Ther Drug Monit; 2020 Jun; 42(3):360-368. PubMed ID: 32304488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
    Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
    mBio; 2020 May; 11(3):. PubMed ID: 32444382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility and risk of dermatologic medications during the COVID-19 pandemic.
    Goldust M; Hartmann K; Abdelmaksoud A; Navarini AA
    Dermatol Ther; 2020 Nov; 33(6):e13833. PubMed ID: 32537852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.
    Ghazawi FM; Lim M; Dutz JP; Kirchhof MG
    Int J Dermatol; 2020 Sep; 59(9):1043-1056. PubMed ID: 32621284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists.
    Zahedi Niaki O; Anadkat MJ; Chen ST; Fox LP; Harp J; Micheletti RG; Nambudiri VE; Pasieka HB; Shinohara MM; Rosenbach M; Merola JF
    J Am Acad Dermatol; 2020 Oct; 83(4):1150-1159. PubMed ID: 32569797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral antiviral treatments for COVID-19: opportunities and challenges.
    Rahmah L; Abarikwu SO; Arero AG; Essouma M; Jibril AT; Fal A; Flisiak R; Makuku R; Marquez L; Mohamed K; Ndow L; Zarębska-Michaluk D; Rezaei N; Rzymski P
    Pharmacol Rep; 2022 Dec; 74(6):1255-1278. PubMed ID: 35871712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
    Huang F; Li Y; Leung EL; Liu X; Liu K; Wang Q; Lan Y; Li X; Yu H; Cui L; Luo H; Luo L
    Pharmacol Res; 2020 Aug; 158():104929. PubMed ID: 32442720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
    Scarabel L; Guardascione M; Dal Bo M; Toffoli G
    Int J Infect Dis; 2021 Mar; 104():441-451. PubMed ID: 33476760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders.
    Ouyang J; Zaongo SD; Harypursat V; Li X; Routy JP; Chen Y
    Front Public Health; 2022; 10():945448. PubMed ID: 36003629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
    Perricone C; Triggianese P; Bartoloni E; Cafaro G; Bonifacio AF; Bursi R; Perricone R; Gerli R
    J Autoimmun; 2020 Jul; 111():102468. PubMed ID: 32317220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.
    Gresham LM; Marzario B; Dutz J; Kirchhof MG
    J Am Acad Dermatol; 2021 Jun; 84(6):1652-1666. PubMed ID: 33482251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.